{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:19:52Z","timestamp":1773037192599,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>QTc prolongation can trigger potentially lethal arrhythmias. Almost all azole antifungals, which are used in vulnerable patients, prolong the QTc interval and thus, may increase arrhythmia risk. The Tisdale-risk-score allows to identify patients at risk for drug-induced QTc prolongation but has not yet been investigated in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the sensitivity and specificity of the Tisdale-score with regard to detected QTc prolongations in patients prescribed systemic azole antifungals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For six months (12\/23-05\/24), prescriptions of systemic azole antifungals were retrospectively recorded in adult inpatients of all medical specialties of a university hospital. Risk factors for QTc prolongation, including concomitant drugs and ECGs, were documented and the Tisdale-score and its sensitivity and specificity were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the study period, 319 systemic azole prescriptions (cases) were recorded for 259 patients. The median age of all cases was 61 years, 45% (143) were female. Including the systemic azole, a prescription of \u22652 QT-drugs was present in 283 (89%) cases. The median Tisdale-score was 7 (moderate risk). ECGs after azole initiation were available in 149 cases. Out of these, relevant QTc prolongations occurred in 7 cases (4.7%). Sensitivity of the Tisdale-score was 100%, specificity 30%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients prescribed systemic azole antifungals are at risk of QTc prolongation due to regular use of multiple QT-drugs. However, relevant QTc prolongations were rare in the patient population studied. The Tisdale-score achieved a good sensitivity for the identification of patients at risk for QTc prolongation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1685152","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:29:17Z","timestamp":1773034157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tisdale-score-based risk stratification of QTc prolongations in hospitalized patients receiving azole antifungal therapy\u2014a retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Julian","family":"Steinbrech","sequence":"first","affiliation":[{"name":"Hospital Pharmacy, LMU University Hospital","place":["Munich, Germany"]},{"name":"Doctoral Program Clinical Pharmacy, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Amann","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, LMU","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Irlbeck","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Clau\u00df","sequence":"additional","affiliation":[{"name":"Department of Cardiology, LMU University Hospital","place":["Munich, Germany"]},{"name":"DZHK (German Center for Cardiovascular Research), Munich Heart Alliance","place":["Munich, Germany"]},{"name":"Institute of Surgical Research at the Walter-Brendel-Center of Experimental Medicine, LMU University Hospital","place":["Munich, Germany"]},{"name":"Member of the European Reference Network for Rare, low prevalence and complex Diseases of the Heart (ERN GUARD-Heart)","place":["Munich, Germany"]},{"name":"Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea","family":"Strobach","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, LMU University Hospital","place":["Munich, Germany"]},{"name":"Doctoral Program Clinical Pharmacy, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can Pharm J (Ott)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0199028","DOI":"10.1371\/journal.pone.0199028","article-title":"QTc interval prolongation in critically ill patients: prevalence, risk factors and associated medications","volume":"13","author":"Fernandes","year":"2018","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14740\/jocmr3338w","article-title":"Impact of drug induced long QT syndrome: a systematic review","volume":"10","author":"Arunachalam","year":"2018","journal-title":"J Clin Med Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40801-021-00234-x","article-title":"Drug-Associated QTc prolongation in geriatric hospitalized patients: a cross-sectional study in internal medicine","volume":"8","author":"Rossi","year":"2021","journal-title":"Drugs Real World Outc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/11598160-000000000-00000","article-title":"Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs","volume":"35","author":"Tisdale","year":"2012","journal-title":"Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","article-title":"High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in practice (QTIP) study","volume":"40","author":"Pickham","year":"2012","journal-title":"Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/postgradmedj-2017-135208","article-title":"QTc prolongation in acute medical admissions: an often overlooked and potentially serious finding","volume":"94","author":"Coughlan","year":"2018","journal-title":"Postgrad Med J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40264-022-01215-x","article-title":"Use of electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in clinical practice: systematic review and meta-analysis","volume":"45","author":"Putnikovic","year":"2022","journal-title":"Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s11096-024-01788-w","article-title":"Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study","volume":"46","author":"Steinbrech","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"B11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/jcm14020339","article-title":"Risk stratification of QTc prolongations in hospitalized cardiology and gastroenterology patients using the tisdale score-a retrospective analysis","volume":"14","author":"Steinbrech","year":"2025","journal-title":"J Clin Med"},{"key":"B12","volume-title":"Antimykotische Prim\u00e4rprophylaxe bei Patienten mit H\u00e4matologischen Neoplasien","author":"Stemler","year":"2023"},{"key":"B13","volume-title":"Invasive Pilzinfektionen\u2014therapie","author":"Ruhnke","year":"2020"},{"key":"B14","volume-title":"QTdrugs List","author":"Woosley","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"B16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"B18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","article-title":"Development of a risk score for QTc-prolongation: the RISQ-PATH study","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","article-title":"A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model","volume":"84","author":"Vandael","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.22541\/au.163879967.78380326\/v1","article-title":"Development and validation of a QTc-prolongation risk score to optimize interruptive medication alerts","author":"Aboujaoude","year":"2021","journal-title":"Authorea"},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12911-020-01181-3","article-title":"Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice","volume":"20","author":"Berger","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s11096-018-0692-y","article-title":"Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs","volume":"40","author":"Bindraban","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","article-title":"Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients","volume":"7","author":"Tisdale","year":"2014","journal-title":"Circ Cardiovasc Qual Outc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","article-title":"An analysis of the time-relations of electrocardiograms","volume":"2","author":"Bazett","year":"1997","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.hrthm.2017.03.014","article-title":"Acquired long QT syndrome in hospitalized patients","volume":"14","author":"Yu","year":"2017","journal-title":"Heart Rhythm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ccl.2006.03.005","article-title":"Status of computerized electrocardiography","volume":"24","author":"Hongo","year":"2006","journal-title":"Cardiol Clin"},{"key":"B28","doi-asserted-by":"publisher","first-page":"euad213","DOI":"10.1093\/europace\/euad213","article-title":"Manual vs. automatic assessment of the QT-interval and corrected QT","volume":"25","author":"Neumann","year":"2023","journal-title":"Europace"},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/1573403x10666140514103612","article-title":"The measurement of the QT interval","volume":"10","author":"Postema","year":"2014","journal-title":"Curr Cardiol Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.hrthm.2005.02.011","article-title":"Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one","volume":"2","author":"Viskin","year":"2005","journal-title":"Heart Rhythm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.hrthm.2008.03.037","article-title":"Accurate electrocardiographic assessment of the QT interval: teach the tangent","volume":"5","author":"Postema","year":"2008","journal-title":"Heart Rhythm"},{"key":"B32","volume-title":"The Clinical Evaluation of QT\/QTc Interval Prolongation an Proarrhythmic Potential for Non-Antiarrhythmic Drugs. ICH Harmonised Tripartite Guideline E14. Step 4 Version","year":"2005"},{"key":"B33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.hrthm.2009.02.044","article-title":"The QT interval: too long, too short or just right","volume":"6","author":"Viskin","year":"2009","journal-title":"Heart Rhythm"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1685152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:29:18Z","timestamp":1773034158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1685152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1685152"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1685152","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1685152"}}